...
首页> 外文期刊>Acta bio-medica: Atenei Parmensis >Hypersensitivity pneumonia and HIV infection in occupational settings: a case report from northern Italy
【24h】

Hypersensitivity pneumonia and HIV infection in occupational settings: a case report from northern Italy

机译:职业环境中的超敏性肺炎和艾滋病毒感染:意大利北部的病例报告

获取原文

摘要

We describe a case of relapsing hypersensitivity pneumonitis (HP) manifesting as a reconstitution inflammatory syndrome (IRIS) in a HIV infected patient receiving antiretroviral therapy (HAART). The patient, who works as a farmer since the early 20s, was diagnosed with HP at age 23: after an initial steroid therapy, a long lasting clinical regression followed. At age 32, HIV positivity was diagnosed, with HAART starting only at age 38 (initially, lamivudine 300 mg/daily + zidovudine 300 mg b.i.d.). In the following 15 years, CD4+ count remained 500 cells/μL until therapy was shifted to ritonavir 100 mg b.i.d + fosamprenavir 700 mg b.i.d. A six-months long increase in the CD4+ count (600 cells/μL) with undetectable viral load then followed. Eventually, the patient developed cough and slowly worsening dyspnoea. Laboratory exams (serum T cell lymphocyte count 83%, CD8+ 45-51%; serum IgG for M faeni =78 mg/L and P notatum 200 mg/L) and high-resolution computer tomography (HRCT) were compatible with relapsing HP. The working tasks were modified avoiding any contact with allergens, then achieving a 6 months long clinical regression. Detectable HIV load (62 copies/mL) was identified at follow-up, and emtricitabine 200 mg/tenofovir disoproxil fumarate 245 mg s.i.d. was added to HAART. Respiratory involvement newly relapsed. HAART was shifted to emtricitabine 200 mg/tenofovir disoproxil fumarate 245 mg s.i.d. and raltegravir 400 mg b.i.d. Within several weeks, signs and symptoms resolved almost completely (peripheral oxygen saturation 95%: CD4+ count remained 600 cells/μL with CD8+ count steadily 50% and CD4+/CD8+ ratio 55%).
机译:我们描述了一例在接受抗逆转录病毒治疗(HAART)的HIV感染患者中表现为重构性炎症综合症(IRIS)的复发性超敏性肺炎(HP)。该患者自20年代初开始担任农民,在23岁时被诊断出患有HP:最初接受类固醇治疗后,随后进行了长期的临床消退。在32岁时,诊断出HIV阳性,HAART仅在38岁时开始(最初,拉米夫定300毫克/天+齐多夫定300毫克b.i.d.)。在随后的15年中,CD4 +计数保持<500细胞/μL,直到治疗转向利托那韦100 mg b.i.d + fosamprenavir 700 mgb.i.d。随后出现了六个月长的CD4 +计数增加(> 600个细胞/微升),并且病毒载量无法检测。最终,患者出现咳嗽并逐渐加重呼吸困难。实验室检查(血清T细胞淋巴细胞计数83%,CD8 + 45-51%; M faeni的血清IgG = 78 mg / L,P notatum> 200 mg / L)和高分辨率计算机断层扫描(HRCT)与复发型HP兼容。修改工作任务,避免与过敏原接触,然后实现6个月的临床消退。在随访中鉴定出可检测到的HIV载量(62份/ mL),恩曲他滨200 mg /替诺福韦富马酸替诺福韦酯245 mg s.i.d.已添加到HAART。呼吸系统受累新近复发。将HAART移至依曲他滨200 mg /替诺福韦富马酸替索非尔245 mg s.i.d.和raltegravir 400 mg b.i.d.在几周内,体征和症状几乎完全消失(外周血氧饱和度> 95%:CD4 +计数保持> 600细胞/μL,CD8 +计数稳定地<50%,CD4 + / CD8 +比率> 55%)。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号